Ranger Investment Management L.P. Purchases Shares of 173,988 Mesa Laboratories, Inc. $MLAB

Ranger Investment Management L.P. acquired a new position in Mesa Laboratories, Inc. (NASDAQ:MLAB) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 173,988 shares of the medical instruments supplier’s stock, valued at approximately $17,321,000.

Several other institutional investors also recently modified their holdings of the company. Globeflex Capital L P acquired a new position in shares of Mesa Laboratories in the second quarter valued at $1,153,000. Diamond Hill Capital Management LLC Investment Advisor bought a new stake in Mesa Laboratories in the 2nd quarter valued at $15,507,000. Bank of New York Mellon Corp bought a new stake in Mesa Laboratories in the 2nd quarter valued at $4,540,000. Wasatch Advisors LP raised its stake in shares of Mesa Laboratories by 125.8% in the 2nd quarter. Wasatch Advisors LP now owns 115,668 shares of the medical instruments supplier’s stock valued at $11,515,000 after buying an additional 64,435 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Mesa Laboratories by 5.9% during the 1st quarter. Bank of America Corp DE now owns 57,871 shares of the medical instruments supplier’s stock worth $5,117,000 after acquiring an additional 3,207 shares during the period. Institutional investors and hedge funds own 90.60% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Wells Fargo & Company increased their price target on shares of Mesa Laboratories from $94.00 to $110.00 and gave the stock an “equal weight” rating in a research report on Friday, August 14th. Weiss Ratings raised Mesa Laboratories from a “sell (d)” rating to a “hold (c-)” rating in a report on Tuesday, August 11th. Finally, Wall Street Zen lowered Mesa Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 15th. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Mesa Laboratories presently has an average rating of “Hold” and an average target price of $110.00.

Mesa Laboratories Price Performance

MLAB opened at $124.76 on Monday. The firm has a market cap of $698.66 million, a price-to-earnings ratio of 148.53 and a beta of 0.92. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.32 and a current ratio of 1.79. The firm’s 50-day simple moving average is $101.47 and its 200-day simple moving average is $97.35. Mesa Laboratories, Inc. has a twelve month low of $58.83 and a twelve month high of $124.89.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings results on Monday, August 10th. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter. The firm had revenue of $60.14 million during the quarter. Mesa Laboratories had a net margin of 1.92% and a return on equity of 22.72%.

Mesa Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Monday, August 31st will be issued a dividend of $0.16 per share. The ex-dividend date of this dividend is Monday, August 31st. This represents a $0.64 annualized dividend and a dividend yield of 0.5%. Mesa Laboratories’s dividend payout ratio (DPR) is presently 76.19%.

Insider Buying and Selling

In other news, Director R Tony Tripeny bought 900 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was bought at an average price of $113.69 per share, for a total transaction of $102,321.00. Following the completion of the purchase, the director owned 6,298 shares of the company’s stock, valued at approximately $716,019.62. The trade was a 16.67% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Siddhartha Kadia bought 7,093 shares of Mesa Laboratories stock in a transaction dated Thursday, August 13th. The stock was acquired at an average cost of $112.80 per share, for a total transaction of $800,090.40. Following the completion of the acquisition, the chief executive officer directly owned 7,093 shares in the company, valued at $800,090.40. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold a total of 15,370 shares of company stock valued at $1,570,213 in the last ninety days. 2.80% of the stock is owned by corporate insiders.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.